PT  - JOURNAL ARTICLE
AU  - Naotoshi Nakamura
AU  - Hyeongki Park
AU  - Kwang Su Kim
AU  - Yoshitaka Sato
AU  - Yong Dam Jeong
AU  - Shoya Iwanami
AU  - Yasuhisa Fujita
AU  - Tianchen Zhao
AU  - Yuta Tani
AU  - Yoshitaka Nishikawa
AU  - Chika Yamamoto
AU  - Yurie Kobashi
AU  - Takeshi Kawamura
AU  - Akira Sugiyama
AU  - Aya Nakayama
AU  - Yudai Kaneko
AU  - Kazuyuki Aihara
AU  - Shingo Iwami
AU  - Masaharu Tsubokura
TI  - A personalized antibody score for predicting individual COVID-19 vaccine-elicited antibody levels from basic demographic and health information
AID  - 10.1101/2022.07.05.22277283
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.07.05.22277283
4099  - http://medrxiv.org/content/early/2022/07/06/2022.07.05.22277283.short
4100  - http://medrxiv.org/content/early/2022/07/06/2022.07.05.22277283.full
AB  - Antibody titers wane after two-dose COVID-19 vaccinations, but individual variation in vaccine-elicited antibody dynamics remains to be explored. Here, we created a personalized antibody score that enables individuals to infer their antibody status by use of a simple calculation. We recently developed a mathematical model of B cell differentiation to accurately interpolate the longitudinal data from a community-based cohort in Fukushima, Japan, which consists of 2,159 individuals who underwent serum sampling two or three times after a two-dose vaccination with either BNT162b2 or mRNA-1273. Using the individually reconstructed time course of the vaccine-elicited antibody response, we first elucidated individual background factors that contributed to the main features of antibody dynamics, i.e., the peak, the duration, and the area under the curve. We found that increasing age was a negative factor and a longer interval between the two doses was a positive factor for individual antibody level. We also found that the presence of underlying disease and the use of medication affected antibody levels negatively, whereas the presence of adverse reactions upon vaccination affected antibody levels positively. We then applied to these factors a recently proposed computational method to optimally fit clinical scores, which resulted in an integer-based score that can be used to evaluate the antibody status of individuals from their basic demographic and health information. This score can be easily calculated by individuals themselves or by medical practitioners. There is a potential usefulness of this score for identifying vulnerable populations and encouraging them to get booster vaccinations.Significance statement Different individuals show different antibody titers even after the same COVID-19 vaccinations, making some individuals more prone to breakthrough infections than others. Such variability remains to be clarified. Here we used mathematical modeling to reconstruct individual post-vaccination antibody dynamics from a cohort of 2,159 individuals in Fukushima, Japan. Machine learning identified several positive and negative factors affecting individual antibody titers. Positive factors included adverse reactions after vaccinations and a longer interval between two vaccinations. Negative factors included age, underlying medical conditions, and medications. We combined these factors and developed an “antibody score” to estimate individual antibody dynamics from basic demographic and health information. This score can help to guide individual decision-making about taking further precautions against COVID-19.Competing Interest StatementYKaneko is employed by Medical & Biological Laboratories, Co. (MBL, Tokyo, Japan). MBL imported the testing material used in this research. YKaneko participated in the testing process; however, he did not engage in the research design and analysis. YKobashi and MT received a research grant from Pfizer Health Research Foundation for research not associated with this work.Funding StatementThis study was supported by Medical & Biological Laboratories Co., Ltd., Shenzhen YHLO Biotech Co., Ltd., the distributor and manufacturer of the antibody measurement system (iFlash 3000), Research Center for Advanced Science and Technology in the University of Tokyo, and in part by Scientific Research (KAKENHI) B 18H01139 (to S.I.), 16H04845 (to S.I.); Scientific Research in Innovative Areas 20H05042 (to S.I.); AMED Strategic International Brain Science Research Promotion Program 22wm0425011s0302 (to K.A.); AMED JP22dm0307009 (to K.A.); AMED CREST 19gm1310002 (to S.I.); AMED Development of Vaccines for the Novel Coronavirus Disease, 21nf0101638h0001 (to M.T.), 21nf0101638s0201 (to S.I.); AMED Japan Program for Infectious Diseases Research and Infrastructure, 22wm0325007h0001 (to S.I.), 22wm0325004s0201 (to S.I.), 22wm0325012s0301 (to S.I.), 22wm0325015s0301 (to S.I.); AMED Research Program on Emerging and Re-emerging Infectious Diseases 22fk0108140s0802 (to S.I.); AMED Research Program on HIV/AIDS 22fk0410052s0401 (to S.I.); AMED Program for Basic and Clinical Research on Hepatitis 22fk0210094 (to S.I.); AMED Program on the Innovative Development and the Application of New Drugs for Hepatitis B 22fk0310504h0501 (to S.I.); AMED Research Program on Hepatitis 19fk0210036h0502 (to S.I.), 19fk0310114h0103 (to S.I.); JST 24 MIRAI JPMJMI22G1 (to S.I.); Moonshot R&D JPMJMS2021 (to K.A. and S.I.) and JPMJMS2025 (to S.I.); The National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (2022R1C1C2003637) (to K.S.K.); Shin-Nihon of Advanced Medical Research (to S.I.); SECOM Science and Technology Foundation (to S.I.); The Japan Prize Foundation (to S.I.); and Kowa Co (to M.T.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the ethics committees of Hirata Central Hospital (number 2021-0611-1) and Fukushima Medical University (number 2021-116). This study was conducted in accordance with the Code of Ethics of the World Medical Association (Declaration of Helsinki).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors